Latest Xenon Stories
WOBURN, Mass., Jan. 12, 2011 /PRNewswire/ -- Energetiq Technology, Inc., a developer and manufacturer of ultrahigh-brightness light sources for advanced technology applications, today announced an addition to its Laser-Driven Light Source (LDLS(TM)) product family: the EQ-99FC.
CARLSBAD, Calif. and VANCOUVER, Canada, Nov. 16, 2010 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Xenon Pharmaceuticals Inc.
WOBURN, Mass., Nov. 11, 2010 /PRNewswire/ -- Energetiq Technology, Inc., a developer and manufacturer of ultrahigh-brightness light sources for advanced technology applications, today announced that it has been named a finalist in the 2010 Prism Award International Competition.
DANVERS, Mass., Oct.
SALEM, N.H., Sept.
VANCOUVER, Canada, Aug. 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.
LEHIGH VALLEY, Pa., July 27 /PRNewswire-FirstCall/ -- Air Products (NYSE: APD) today announced the addition of xenon difluoride (XeF2) to its portfolio of electronic materials. XeF2 is used as an etching gas, primarily in the Micro Electro Mechanical Systems (MEMS) market.
VANCOUVER, May 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce today that it has appointed Tarek S. Mansour as Executive Vice President, Research and Development. "We are delighted to welcome Tarek to the Xenon team," commented Simon Pimstone, Xenon's President and CEO.
British doctors say they have prevented brain injury in a baby boy who was born in critical condition by using an inert gas.